Purpose: A novel classification system has been proposed to stratify patients undergoing palliative radiation therapy based on their pain response and time to progression. This study used prospective observational data to quantify quality of life (QoL) changes associated with pain response and the classification system.
Methods And Materials: Between August 2021 and September 2022, 366 painful lesions with a numerical rating scale of 2 or more from the 261 eligible patients underwent palliative radiation therapy. Patients were followed-up prospectively at 2, 4, 12, 24, 36, and 52 weeks postradiation therapy, with EORTC QLQ-C15-PAL and QLQ-BM22 questionnaires obtained simultaneously with pain response assessments. The primary endpoint was defined as the global health status/QoL improvements at 12 weeks based on minimally clinically important differences and compared by the pain response (responders vs. nonresponders) and by class 1 (no opioids, no reirradiation, n = 89), 2 (neither class 1 nor 3, n = 211), and 3 (opioids and reirradiation, n = 66).
Results: With a median follow-up time of 21 weeks for pain response and 13 weeks for QoL assessment, 1773 pairs of QLQ-C15-PAL and QLQ-BM22 questionnaires were collected. The QoL assessment at baseline was covered with 97% (355/366) of lesions and 67% (183/273) at 12 weeks: this compliance was lower in nonresponders than in responders (57% vs. 72%, P = .004) and highest in class 1, followed by classes 2 and 3 (70% vs. 44% vs. 39%, P = .001). The improvement rate was significantly different by class, with class 3 having the lowest in all subscales except nausea and psychosocial aspects: the improvement rate of global health status/QoL was 33% in class 1, 31% in class 2, and 20% in class 3, P = .001).
Conclusions: The QoL changes associated with pain response and the classification system were identified, suggesting that the classification system may help identify populations more or less likely to improve QoL, in addition to separating pain response rates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2024.11.102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of adalimumab in pediatric non-infectious uveitis with and without anterior segment inflammation.
BMC Ophthalmol
January 2025
Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, Xi'an, 710004, China.
Background: This study aimed to identify the clinical characteristics of cases that is related to the response rate of adalimumab (ADA) treatment.
Methods: A retrospective review of medical records was conducted for pediatric patients with non-infectious uveitis undergoing ADA treatment for a minimum of six months. The patients were stratified into two groups: those with anterior segment inflammation (ASI+) and those without anterior segment inflammation (ASI-).
Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.
Inflammopharmacology
January 2025
Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.
Osteoarthritis, the most common arthritic condition, is an age-related progressive disease characterized by the loss of cartilage and synovial inflammation in the knees and hips. Development of pain, stiffness, and considerably restricted mobility of the joints are responsible for the production of matrix metalloproteinases and cytokines. Although several treatments are available for the management of this disease condition, they possess limitations at different levels.
View Article and Find Full Text PDFPain management in percutaneous nephrolithotomy - an approach rooted in pathophysiology.
Nat Rev Urol
January 2025
Department of Urology, Lenox Hill Hospital/Northwell Health, New York, NY, USA.
Pain related to percutaneous nephrolithotomy (PCNL) is multifactorial and poorly elucidated. However, understanding the pathophysiology of pain can enable a practical approach to pain management, which can be tailored to each patient. A number of potential mechanisms underlie pain perception in PCNL, and these mechanisms can be leveraged at various points on the perioperative care pathway.
View Article and Find Full Text PDFCiprofol, a novel γ-aminobutyric acid receptor agonist, outperforms propofol with minimal cardiovascular effects, higher potency, reduced injection pain, and a broader safety margin. Despite these advantages, ciprofol's clinical research is still emerging. This study compares the median effective dose (ED) and adverse reactions of ciprofol and propofol, in conjunction with sufentanil, for suppressing cardiovascular responses during tracheal intubation.
View Article and Find Full Text PDFThe immune-inflammatory responses on the hypothalamic-pituitary-adrenal axis and the neurovascular unit in perioperative neurocognitive disorder.
Exp Neurol
January 2025
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address:
Perioperative neurocognitive disorders (PNDs) refer to a wide spectrum of cognitive impairment persisting days to even after a year postoperative with significant morbidity and mortality. However, despite much efforts involving perioperative managements, PNDs are still prevalent with no standard preventative and therapeutic strategy. To overcome PNDs, a better understanding of pathophysiology of PNDs is crucial and a large number of studies have proven that immune-inflammatory responses from surgical stress are involved in the abnormal activation of the hypothalamic-pituitary-adrenal (HPA) axis and destabilization of neurovascular unit (NVU) that lead to PNDs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!